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Abstract 
Sepsis is a severe illness during the neonatal period. Despite significant advances in 
the care of newborn infants, sepsis remains a leading cause of neonatal morbidity and 
mortality. The overall incidence of neonatal sepsis ranges from 1 to 5 cases per 1,000 births 
and case fatality rates (CFRs) range from 2 % to 60 %. Both rates depend on multiple factors, 
such as pathogen distribution, gestational age, Streptococcus agalactiae (group B 
Streptococcus, GBS) carriage rates and prevalence of other common specific pathogens. 
Most types of microorganisms can cause sepsis, including bacteria, fungi, viruses and 
parasites, such as those that cause malaria. Bacteria such as Streptococcus pneumoniae, 
Haemophilus influenzae, Staphylococcus aureus, Escherichia coli, Salmonella and Neisseria 
meningitidis are the most common etiological pathogens. Manifestations of sepsis and septic 
shock can be the fatal frequent pathway of infections with seasonal influenza viruses, dengue 
viruses and highly transmissible pathogens of public health concern such as avian and swine 
influenza viruses, severe acute respiratory syndrome coronavirus, Middle East respiratory 
syndrome coronavirus and most recently, Ebola and yellow fever viruses. 
It is descriptive, non-experimental study.  The aim of it is to specify the etiologic 
factors, clinical manifestation, diagnostic criteria and treatment of sepsis. 
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Based on the results of the study conclusion is that the use of non-culture based 
diagnostics and sepsis scores to predict and diagnose septic neonates are areas of active 
investigation. The next frontier for antibiotic stewardship in the neonatal intensive care unit 
must be development of strategies to decrease antibiotic use and minimise adverse effects by 
a thorough study of duration of therapy.  
Key words. Neonatal sepsis, complete blood count, blood culture, antimicrobial 
therapy. 
 
Sepsis arises when the body’s response to infection injures its own tissues and organs. 
It can lead to septic shock, multiple organ failure and death, if not recognized early and 
managed promptly [1]. 
An international consensus has recently recommended that sepsis should be defined as 
“life-threatening organ dysfunction caused by a dysregulated host response to infection” and 
septic shock as “a subset of sepsis in which particularly profound circulatory, cellular, and 
metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone” 
[2]. Both definitions are accompanied by clinical criteria to translate them into practice to 
support diagnosis and clinical management during patient care.  
Sepsis is a severe illness during the neonatal period. Despite significant advances in 
the care of newborn infants, sepsis remains a leading cause of neonatal morbidity and 
mortality, particularly among very low-birth-weight (VLBW) preterm infants. The overall 
incidence of neonatal sepsis ranges from 1 to 5 cases per 1,000 livebirths [3] and case fatality 
rates (CFRs) range from 2 % to 60 %. Both rates depend on multiple factors, such as 
pathogen distribution, gestational age, Streptococcus agalactiae (group B Streptococcus, 
GBS) carriage rates and prevalence of other common specific pathogens [4, 5]. Children 
admitted to the NICU are normally in a serious condition or premature; the prevalence of 
sepsis amonglong-term hospitalized children may be as high as 30%,with a mortality rate as 
high as 50%, and survivors experience serious sequelae [6 – 8]. 
Most types of microorganisms can cause sepsis, including bacteria, fungi, viruses and 
parasites, such as those that cause malaria. Bacteria such as Streptococcus pneumoniae, 
Haemophilus influenzae, Staphylococcus aureus, Escherichia coli, Salmonella spp. and 
Neisseria meningitidis are the most common etiological pathogens. Manifestations of sepsis 
and septic shock can be the fatal frequent pathway of infections with seasonal influenza 
viruses, dengue viruses and highly transmissible pathogens of public health concern such as 
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avian and swine influenza viruses, severe acute respiratory syndrome coronavirus, Middle 
East respiratory syndrome coronavirus and most recently, Ebola and yellow fever viruses [1].  
The Eunice Kennedy Shriver National Institute of Child Health and Human 
Development Neonatal Network and theVermont Oxford Network define neonatal early-onset 
sepsis (EOS) as the onset of signsand symptoms of sepsis with an associated positive culture 
result at or before age 72 hours. Late-onset sepsis (LOS) is defined as the onset of signs or 
symptoms of sepsis after age 72hour [9]. EOS is further divided into very early onset (VEOS, 
0–2 days) and other EOS (3–6 days), while LOS is sometimes further divided to age groups 
of 7–30 days and 31–90 days [10]. Another acceptable classification differentiates between 
hospital-acquired and community acquired sepsis [11]. The incidence of EOS in the United 
States is estimated to be 0.98 cases per1,000 live births overall and 10.96 cases per 1,000 live 
births among VLBW infants [12]. In addition, more than one-fifth (21%) of VLBW infants 
have at least one episode oflate-onset culture-proven sepsis [13]. 
Vulnerability of the Neonate are: 
- Immature innate immune system: Reduced phagocytic and opsonisation activity, low 
complement levels, and immature cell mediated and humoral immunity.  
- Poor barrier to infection: Fragile immature skin easily susceptible to invasion of 
organism, immature mucosal barriers and reduced levels if secretory immunoglobulins, 
immature ciliary function with reduced ability to clear secretions and poorly developed blood 
brain barrier.  
Presence of the following risk factors has been associated with an increased risk of 
EOS.  
 Low birth weight (<2500gms) or prematurity.  
 Febrile illness in the mother 2 weeks prior to delivery.  
 Foul smelling and / or meconium stained liquor.  
 Prolonged rupture of membrane (>24 hours).  
 More than 3 vaginal examinations during labor.  
 Prolonged and difficult delivery with instrumentation [14]. 
The burden of LOS is significant in developed [15,16] and developing nations of the 
world [17]. The incidence of LOS varies inversely with gestational age and birth weight. The 
important risk factors for LOS in preterm infantsare intravascular catheters, delayed 
commencement of enteral feeds, prolonged use of parenteral nutrition, prolonged ventilation, 
and surgery.1 Although the predominant organism causing LOS is coagulase-negative 
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staphylococci, other organisms such as Staphylococcus aureus, Gramnegative bacteria, and 
fungi also are important [18]. 
Neonatal sepsis (NS) is an inflammation-induced systemic inflammatory response 
syndrome and an important cause of neonatal deaths, this condition comprises systemic 
poisoning symptoms caused by alarge number of toxins produced by bacteria upon entry into 
the blood stream, growth, and reproduction. As the neonatal blood–brain barrier is not 
completely developed,purulent meningitis is easily contracted and represents agreat threat to 
the life and health of children, particularly preterm children [3].  
Neonates with bacterial sepsis might show non-specific signs and symptoms or focal 
signs of infection, including temperature instability, hypotension, poor perfusion with pallor 
and mottled skin, metabolic acidosis, tachycardia or bradycardia, apnoea, respiratory distress, 
grunting, cyanosis, irritability, lethargy, seizures, feeding intolerance, abdominal distention, 
jaundice, petechiae, purpura, and bleeding (table 1).  
 
Table 1: Initial signs and symptoms of infection in newborn infants 
Symptoms  
General  Fever, temperature instability; “not doing well”, poor feeding, or 
oedema  
Gastrointestinal system  Abdominal distention, vomiting, diarrhoea, or hepatomegaly  
Respiratory system  Apnoea, dyspnoea, tachypnoea, retractions, flaring, grunting, or 
cyanosis  
Renal system  Oliguria  
Cardiovascular system  Pallor, mottling, cold, clammy skin, tachycardia, hypotension, 
or bradycardia  
CNS  Irritability, lethargy, tremors, seizures, hyporeflexia, hypotonia, 
abnormal Moro reflex, irregular respirations, full fontanel, or 
high-pitched cry  
Haematological system  Jaundice, splenomegaly, pallor, petechiae, purpura, or bleeding  
 
Initial symptoms might be few and could include apnoea alone or tachypnoea with 
retractions, nasal flaring, grunting, or tachycardia. Later complications of sepsis might include 
respiratory failure, pulmonary hypertension, cardiac failure, shock, renal failure, liver 
dysfunction, cerebral oedema or thrombosis, adrenal haemorrhage or insufficiency, bone 
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marrow dysfunction (neutropenia, thrombocytopenia, anaemia), and disseminated 
intravascular coagulation.  
Non-infectious presentations of organ failure might mimic the clinical presentation of 
neonatal sepsis. Additionally, infectious and non-infectious causes might coexist in the same 
host. For example, clinical observations have shown that respiratory distress syndrome 
secondary to surfactant deficiency might be present with bacterial pneumonia [19].  
Adequate and timely diagnosis of neonatal sepsis remainsan important challenge to the 
clinician especiallyin developing countries. Blood culture, which is the gold standard for 
definitive diagnosis, takes at least 48hours up to 6 days, by which time the infection may have 
progressed with consequences on the morbidity and mortality of the neonates. Some gold 
standard tests (eg, positive bacterial or viral cultures) may take some time to become available 
or may be very expensive, which can increase the value of a test that can be performed in 
expensively and rapidly [20]. 
It should be stated, however, that blood culture sampling often yields false-negative 
results, and clinical signs of infectionare often unspecific. It is therefore a huge challenge to 
diagnose sepsis correctly in early disease states, which would be necessary to initiate prompt 
antimicrobial treatmentand to reduce case fatality rates. 
The complete blood count (CBC) is used by 99% ofthe clinicians as part of their initial 
sepsis evaluation. However, no single marker possesses adequate sensitivity to rule out late-
onset sepsis in VLBW infants [21]. CBC parameters previously associated with late-onset 
sepsis include a total white blood cell count (WBC) < 5000/mm3, an immature 
neutrophil/total neutrophil (I/T) ratio > 0.10 and a platelet count lower than < 100,000/uL 
[22]. The use of CBC in combination with CRP for late onset sepsis evaluation in VLBW 
infants could potentially be more sensitive than each individual test. It is also possible that the 
variation in time (from T0 to T24)of these tests could be clinically useful even when the 
absolute test results are below the cut-off of abnormal values.  
Inflammatory markers such as procalcitonin, C –reactive proteins (CRP) and 
haematological indices have also been used in diagnosing neonatal sepsis [23].  
The advantage of CRP includes its very low serum level in normal infants and rapid 
rise within 6 to 8 hours after the onset of sepsis [24]. Previous studies have shown that 
quantitative serial CRP levels 12 – 24 hours offer the most sensitive and reliable information 
[25]. And can therefore be used as an adjuvant tool to guide physicians.  
Several information sources argue that haematological scoring system (HSS) based on 
total leukocyte count, neutrophils and platelets have also been used to predict neonatal sepsis 
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[23, 24]. In resource limited settings, where blood culture is notroutinely done, relatively in 
expensive screening tools suchas CRP and HSS can be utilized as a screening tools, 
potentially serving lives [26].  
Several studies have investigated different molecular methods for the diagnosis of NS 
since they have an increased sensitivity and the capacity of rapid detection of pathogens. To 
assess their diagnostic accuracy, a systemic review of literature was performed by Cochrane. 
The meta-analysis of 35 studies found a mean sensitivity and specificity of 0.90 and 0.93%, 
respectively. Based on the results, the authors suggest that the molecular tests for the 
diagnosis of NS are unlikely to be used as a triage test (a test that select neonates to undergo 
cultures) because false-negative can delay performance of culture and postpone treatment but 
may perform well as an “add-on” test (a test performed concurrently with cultures) since they 
lead to a rapid detection of pathogens (results are available in 6–8 hours) that may help in 
optimizing treatment [27]. 
Management of a neonate with sepsis includes providing aggressive supportive care, 
antimicrobial therapy and adjuvant therapies.  
Supportive Care consists of: 
 Maintenance of thermo-neutral environment, prevention of hypo or hyperthermia.  
 Maintenance of normoglycemic status (45 to 120 mg/dl).  
 Maintenance of Oxygen saturation (91 to 94%).  
 Maintenance of tissue perfusion and blood pressure using colloids and inotropes.  
 Maintenance of adequate nutrition by enteral feeding if not feasible by parenteral 
nutrition.  
 Blood products to normalize the coagulation abnormalities, correction of anemia and 
thrombocytopenia.  
Antimicrobial therapy of neonatal infections can be divided into the suspected 
(empirical) or known (definitive) pathogens. Consideration of early-onset or late-onset 
presentation and exposures (community versus hospitalised status at the time of symptom 
onset) affects antimicrobial choice. The most important components are a thorough and 
complete history and physical examination as well as cultures of clinical specimens [19]. 
The indications for starting antibiotics in neonates at risk of EOS include:  
 Presence of >3 risk factors for early onset sepsis.  
 Presence of foul smelling liquor.  
 presence of 2 antenatal risk factor and a positive septic screen and `  
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 Strong clinical suspicion of sepsis.  
The indications for Starting Antibiotics in LOS Include  
 Positive septic screen.  
 Strong clinical suspicion of sepsis [14]. 
Although it is preferable to obtain cultures before the initiation of antimicrobial 
therapy to optimize recovery of organisms, antimicrobial therapy administration should not be 
unduly delayed for specimen collection in severely ill neonates in septic shock. In general, 
empirical therapy should be guided by the antimicrobial resistance patterns of bacterial 
isolates commonly detected in the neonatal intensive care unit or in community settings. 
Initial empirical treatment of early-onset bacterial infections should consist of ampicillin and 
an aminoglycoside (usually gentamicin), with third-generation or fourth-generation 
cephalosporin drugs reserved for suspected Gram-negative meningitis. Infections due to 
extended-spectrum β-lactamase-producing Gram-negative bacilli require treatment with 
carbapenems, such as meropenem. Treatment with piperacillin–tazobactam and ampicillin–
sulbactam is being used increasingly among infants admitted to hospital in the neonatal 
intensive care unit; however, the penetration of tazobactam into the CNS is unreliable and 
should not be used for treatment of meningitis. However, the β-lactamase inhibitor sulbactam, 
when combined with ampicillin, does seem to achieve high concentrations in the CSF [28]. 
Health-care-associated infections acquired in a neonatal intensive care unit are more 
likely to be caused by coagulase-negative staphylococci, and less often due to S aureus and 
Gram-negative bacteria. Although bloodstream infections due to coagulase-negative 
staphylococci in preterm infants are associated with substantial short-term morbidity as well 
as long-term neurodevelopmental impairment, they are not associated with increased 
mortality. With improvement in blood culture techniques that provide real-time culture 
results, narrow empirical therapy with a β-lactam antistaphylococcal antibiotic such as 
nafcillin combined with an aminoglycoside, could be initiated in infants not colonised with 
MRSA and altered if pathogen recovery suggests alternative antimicrobial coverage. Such a 
strategy has been shown to reduce vancomycin use in the neonatal intensive care unit [29].  
Fungal infections including candidiasis, aspergillosis, and zygomycoses, should be 
aggressively managed when they are suspected and diagnosed. Empirical antifungal therapy 
with amphotericin deoxycholate can be considered in high-risk infants with risk factors for 
invasive candidiasis. Involvement of a paediatric infectious disease physician, a pharmacist 
with expertise in neonatal infections, and use of a guide containing neonatal dosing by weight 
and gestational age optimises antimicrobial use. Peak and trough measurements of 
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antimicrobials might be useful to minimise toxicity if the antimicrobial will be administered 
for more than 2–3 days and in the treatment of particular infections such as meningitis where 
CSF penetration is needed. Trough measurements might be indicated in infants with 
compromised kidney or liver function [19]. 
It can be concluded that despite the fact that the burden of early-onset sepsis attributed 
to GBS has been reduced because of the widespread implementation of prenatal screening and 
administration of intrapartum antibiotics, missed opportunities for diagnosis and intervention 
still exist. The widespread use of antibiotic prophylaxis raises questions about the emergence 
of resistance among co-colonising organisms and continued active surveillance will be 
important to monitor this concern. The significance of coagulase-negative staphylococci as 
colonising organisms versus pathogens in the neonate remains an important area of 
investigation, especially with concern for emergence of vancomycin resistance.  
The use of non-culture based diagnostics and sepsis scores to predict and diagnose 
septic neonates are areas of active investigation. The next frontier for antibiotic stewardship in 
the neonatal intensive care unit must be development of strategies to decrease antibiotic use 
and minimise adverse effects by a thorough study of duration of therapy. As knowledge of the 
neonatal microbiome emerges, the importance of minimising antibiotic exposure to decrease 
necrotising enterocolitis, as well as other sequelae such as asthma, obesity, inflammatory 
bowel disease, and neurological disorders is paramount. 
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